Allergy & Asthma Specialists have chosen Aerocrine's FENO technology to diagnose eosinophilic airway inflammation in patients with non-specific respiratory symptoms, to predict patient response to corticosteroid therapy, as well as to optimize dosing and assess adherence to anti-inflammatory therapy.

Allergy & Asthma Specialists, specializing in allergic disease, asthma and immunology, has eight locations in Philadelphia and surrounding suburbs.

Allergy & Asthma Specialists president Robert Anolik said measurement of exhaled nitric oxide will enable them to provide optimal asthma management to their patients.

Aerocrine Sales & Marketing director Kathy Hodgdon said in less than two minutes, this test makes it possible for physicians to better help patients living with asthma with appropriate therapy and disease control based on the patients’ individual needs